265 related articles for article (PubMed ID: 29580942)
1. Targeting the replication stress response in cancer.
Forment JV; O'Connor MJ
Pharmacol Ther; 2018 Aug; 188():155-167. PubMed ID: 29580942
[TBL] [Abstract][Full Text] [Related]
2. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
4. Differential Activity of ATR and WEE1 Inhibitors in a Highly Sensitive Subpopulation of DLBCL Linked to Replication Stress.
Young LA; O'Connor LO; de Renty C; Veldman-Jones MH; Dorval T; Wilson Z; Jones DR; Lawson D; Odedra R; Maya-Mendoza A; Reimer C; Bartek J; Lau A; O'Connor MJ
Cancer Res; 2019 Jul; 79(14):3762-3775. PubMed ID: 31123088
[TBL] [Abstract][Full Text] [Related]
5. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
6. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading.
Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG
Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798
[TBL] [Abstract][Full Text] [Related]
7. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
8. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
9. Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies.
Puigvert JC; Sanjiv K; Helleday T
FEBS J; 2016 Jan; 283(2):232-45. PubMed ID: 26507796
[TBL] [Abstract][Full Text] [Related]
10. Targeting ATR in DNA damage response and cancer therapeutics.
Fokas E; Prevo R; Hammond EM; Brunner TB; McKenna WG; Muschel RJ
Cancer Treat Rev; 2014 Feb; 40(1):109-17. PubMed ID: 23583268
[TBL] [Abstract][Full Text] [Related]
11. Targeting replication stress response using polypurine reverse hoogsteen hairpins directed against WEE1 and CHK1 genes in human cancer cells.
Aubets E; Noé V; Ciudad CJ
Biochem Pharmacol; 2020 May; 175():113911. PubMed ID: 32173365
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Targeting ATR in Cancer Therapy.
Karnitz LM; Zou L
Clin Cancer Res; 2015 Nov; 21(21):4780-5. PubMed ID: 26362996
[TBL] [Abstract][Full Text] [Related]
13. DNA REPAIR. Drugging DNA repair.
Jackson SP; Helleday T
Science; 2016 Jun; 352(6290):1178-9. PubMed ID: 27257245
[No Abstract] [Full Text] [Related]
14. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Gralewska P; Gajek A; Marczak A; Rogalska A
J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
16. Differential response of normal and malignant urothelial cells to CHK1 and ATM inhibitors.
Wang WT; Catto JW; Meuth M
Oncogene; 2015 May; 34(22):2887-96. PubMed ID: 25043304
[TBL] [Abstract][Full Text] [Related]
17. Targeting WEE1 Kinase in Cancer.
Matheson CJ; Backos DS; Reigan P
Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
Mak JP; Man WY; Chow JP; Ma HT; Poon RY
Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
[TBL] [Abstract][Full Text] [Related]
19. Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in
Erber J; Steiner JD; Isensee J; Lobbes LA; Toschka A; Beleggia F; Schmitt A; Kaiser RWJ; Siedek F; Persigehl T; Hucho T; Reinhardt HC
Cancer Res; 2019 Oct; 79(19):4855-4868. PubMed ID: 31405847
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis.
Bukhari AB; Lewis CW; Pearce JJ; Luong D; Chan GK; Gamper AM
J Clin Invest; 2019 Mar; 129(3):1329-1344. PubMed ID: 30645202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
